Papillary thyroid cancer (PTC) accounts for ≈90% of all thyroid cancers. The incidence of PTCs <2 cm in size was reported to be disproportionately increased compared with larger PTCs and other types of thyroid cancer, without an increase in mortality from thyroid cancer.
1,2 Several research groups have thus suggested that there has been an overdiagnosis and overtreatment of small PTCs. [1] [2] [3] The question of how to manage patients with small PTCs has therefore become a major clinical issue.
PTCs that are ≤1 cm are called papillary microcarcinomas (PMCs) of the thyroid. In 1993 we proposed and initiated an active surveillance trial for patients with low-risk PMCs without worrisome features. We observed that only a small minority of the patients at our institution (Kuma Hospital in Kobe, Japan) showed disease progression and that these patients were successfully treated with a rescue surgery without mortality from thyroid cancer. [4] [5] [6] The cancer Institute Hospital in Tokyo started a similar trial 2 years after the start of our trial, and they reported similar promising data. 7 Given the safety of the active surveillance management of low-risk PMCs, the 2015 American Thyroid Association (ATA) guidelines made 2 major changes. 8 They decided to no longer require a fine-needle aspiration biopsy for thyroid nodules ≤1 cm even if the nodules show suspicious ultrasound features, unless they are associated with obvious aggressive features. 8 The ATA guidelines also now acknowledge that "an active surveillance management approach can be considered as an alternative to immediate surgery" in patients with low-risk PMCs. 8 We reported that at the 10-year point of active surveillance, 8% and 3.8% of our patients with low-risk PMCs showed tumor enlargement by ≥3 mm and a novel appearance of nodal metastasis, respectively. 5 If these rates remain constant over time, as many as 32% and 15.2% of the patients would show tumor enlargement and nodal metastasis after 40 years of active surveillance, respectively. However, we showed that the disease progression rates are significantly lower in older patients than in younger patients, 5 and thus Contents lists available at ScienceDirect Surgery j o u r n a l h o m e p a g e : w w w. e l s e v i e r. c o m / l o c a t e / y m s y the risk of disease progression would decrease over time. Here, we estimated the lifetime (≤85 years old) probabilities of disease progression during active surveillance according to the patients' age at presentation based on age decade-specific disease progression rates.
Patients and Methods
From January 1993 to December 2011, 1,211 patients who were evaluated as having low-risk PMCs at Kuma Hospital, Japan, chose active surveillance as the alternative to immediate surgery. All had a malignant diagnosis on ultrasound-guided fine needle aspiration cytology. None of them had worrisome features, such as distant or nodal metastasis, significant extrathyroid extension, or aggressive cytology. We cautiously excluded patients with tumors attaching to the trachea or located on the course of the recurrent laryngeal nerve from the candidate for the active surveillance. Since 1993 we have informed and proposed to the patients with low-risk PMCs 2 management options: immediate surgery or active surveillance. The present patients chose active surveillance. The patients included 1,088 females and 123 males with a median age of 56 years (range 20-79 years), and they were followed for a median period of 6.2 years (range 0.5-23.0 years). All patients were followed with an ultrasound examination 6 months after the enrollment and once a year thereafter. Tumor enlargement was defined as increase in tumor size by ≥3 mm. Nodal metastasis was diagnosed with ultrasoundguided fine-needle aspiration cytology and the measurement of the washout of the needle used for the aspiration. 9 Disease progression (DP) was defined as tumor enlargement and/or nodal metastasis.
During the surveillance, 72 patients showed tumor enlargement, 18 patients showed novel nodal metastasis, and 4 of these patients showed both. The numbers of patients in the age-decade groups were as follows: 20s (n = 37), 30s (n = 129), 40s (n = 220), 50s (n = 350), 60s (n = 308), and 70s (n = 167). The period of surveillance and the numbers of patients with tumor enlargement, nodal metastasis and DP in each age group are shown in Table I .
We used the Kaplan-Meier method to calculate the cumulative rates of tumor enlargement, nodal metastasis and DP at the 10-year time point of active surveillance for each age group. Here we express these age decade-specific progression rates for the age groups as R20s, R30s, and so on.
Hypotheses on disease progression
We used 3 hypotheses to describe the possible lifetime rates of disease progression. The assumption that PMCs progress strictly according to the decade-specific rates calculated in this article is referred to hereafter as "Hypothesis A."
The patients who show DP during the initial 10-year period undergo surgical treatment and are thus removed from the active surveillance program thereafter. The assumption that the remaining patients therefore have only tumors that lack a progressive nature and do not progress in the succeeding surveillance is referred to hereafter as "Hypothesis B." Hypothesis B may be possible at least for some of the remaining patients, but applying it to all of the remaining patients might be too optimistic. The actual probability might be values that are between the values estimated with Hypothesis A and those estimated with Hypothesis B. This assumption referred to hereafter as "Hypothesis C."
Lifetime probability of progression according to Hypothesis A
According to Hypothesis A, the lifetime probability of progression for each age group was calculated by the following formula: 1 -the cumulative probability of progression free survival calculated with decade-specific progression rates (R values) until the patients reached their 80s. For example, the lifetime probability of disease progression for patients in their 50s at presentation (55 years old on average) was calculated as: 1 -(1 -R50s) × (1 -R60s) × (1 -R70s).
DP trends over time according to Hypothesis A
With a similar concept, we calculated the trends of DP over the years of active surveillance according to the patients' age at presentation for the decade-periods of surveillance until the patients reached their 80s (85 years old on average). For example, the DP rate at 30 years of active surveillance for patients in their 20s at presentation (25 years old on average) was calculated as:
Lifetime probability of progression according to Hypothesis B and C
According to Hypothesis B, the lifetime probability of DP is the same as the observed cumulative rate of DP at the 10-year time point of surveillance. According to Hypothesis C, the probability values are calculated as (the value of Hypothesis A + the value of Hypothesis B) / 2.
Results
The observed cumulative rates of tumor enlargement at the 10-year time point of active surveillance for the age groups decreased with age from 22.0% for the patients in their 20s to 2.8% in the 70s (Fig 1, Table II ). The estimated lifetime probability of tumor Tumor enlargement was defined as increase in tumor size by ≥3 mm. Disease progression was defined as tumor enlargement and/or novel appearance of nodal metastasis. Data are median (range).
Fig 1.
Proportion of patients whose PMC enlarged by ≥3 mm during active surveillance according to their age at presentation. enlargement also markedly decreased with age from 46.0% in the 20s to 2.8% in the 70s (Table II) . The observed cumulative rates of nodal metastasis at the 10-year time point of active surveillance for the age groups decreased with age from 16.5% in the 20s to 0.6% in the 70s (Fig 2, Table II) . The estimated lifetime probability of nodal metastasis also markedly decreased with age from 26.9% in the 20s to 0.6% in the 70s (Table II) .
The observed cumulative rates of DP at the 10-year time point of active surveillance decreased with age from 36.9% in the 20s to 3.5% in the 70s (Fig 3, Table II ). The estimated lifetime probability of DP calculated according to Hypothesis A also markedly decreased with age from 60.3% in the 20s to 3.5% in the 70s (Table II) .
According to Hypothesis A, the estimated trends in DP over active surveillance according to age at presentation varied markedly depending on the patients' ages at presentation (Fig 4) . The estimated trend curve for patients in their 20s (25 years average) at presentation was steep until they reached 35 years old, and then moderately increased until 55 years and minimally increased thereafter. The estimated trend curves for patients in their 30s or 40s at presentation showed more mild increases with a minimal increase after 55 years (Fig 4) .
According to Hypothesis A, the estimated lifetime probability of DP during active surveillance according to the patients' age at presentation showed a marked decrease with increasing age at presentation, being 60.3% for 25-year-old patients and only 3.5% for 75-year-old patients (Fig 5) .
With Hypothesis B, the estimated lifetime probability of DP is the same as the observed cumulative rate of DP at the 10-year time point of surveillance and was calculated as 36.9% for patients in their 20s at presentation, 13.5% in the 30s, 14.5% in the 40s, 5.6% in the 50s, 6.6% in the 60s, and 3.5% in the 70s at presentation as shown in Fig 5. Hypothesis B may be well possible at least for some patients, but the hypothesis might be too optimistic to apply to all of the remaining patients.
The actual probability might be close to the values that are between the values estimated with Hypothesis A and those estimated with Hypothesis B. This assumption is Hypothesis C. With Hypothesis C, the estimated values were calculated as were 48.6% for patients in their 20s at presentation, 25.3% in the 30s, 20.9% in the 40s, 10.3% in the 50s, 8.2% in the 60s, and 3.5% in the 70s (Fig 5) . Table II Tumor enlargement is defined as increase in tumor size by ≥3 mm. Disease progression is defined as ≥3 mm tumor enlargement and/or appearance of novel nodal metastasis.
Fig 2.
Proportion of patients who showed novel nodal metastasis during active surveillance according to their age at presentation. If one applies Hypotheses B to estimate the lifetime probabilities of tumor enlargement and nodal metastasis according to the age at presentation, the values are the same as the observed cumulative rate of tumor enlargement and nodal metastasis at the 10-year time point of surveillance as shown in Table II . If one applies Hypothesis C to estimate these probabilities, the values can be easily calculated with the values shown in Table II .
Discussion
The 2015 ATA guidelines now acknowledge an active surveillance management approach as an alternative to immediate surgery in patients with low-risk PMC. 8 However, regular follow-up is necessary for PMCs and suspicious nodules ≤1 cm. The most frequently asked questions regarding active surveillance include how long we should survey patients with PMCs and whether most PMCs might become clinically significant over lifetime surveillance. We propose that the surveillance be continued for the patient's lifetime because a small but noteworthy percentage of PMC patients have shown tumor progression. [4] [5] [6] [7] When patients with low-risk PMCs are treated surgically at their presentation, they should still be followed up after the surgery. Up to 66.1% of our patients who underwent immediate surgery required administration of l-thyroxine, 10 most likely for their lifetime.
Regarding whether most PMCs might become clinically significant over a lifetime of surveillance, here we estimated the trends of DP and the lifetime probability of DP during active surveillance, based on age decade-specific cumulative ratios of DP in our >1,200 low-risk PMC patients undergoing active surveillance. The estimated trend curves of DP varied markedly depending on the patient's age at presentation. The curves for patients in their 20s and 30s showed a steep increase for the first 10 or 20 years, with a gradual increase thereafter. The trend curves for the patients in their 40s or older showed a milder increase. The estimated lifetime probability of DP calculated with both Hypothesis A and Hypothesis B fell with each decade of age at presentation.
One might think that 60.3% and 37.1% lifetime probabilities of DP for patients in their 20s and 30s at presentation according to Hypothesis A, respectively, are too high to accept active surveillance. However, these data indicate that ≈40% of the patients in their 20s and 63% of the patients in their 30s will not require surgical treatment for their PMCs during their lifetime. The prediction of Hypothesis B is even better (i.e., ≤63% of the patients in their 20s and 86% of the patients in their 30s at presentation will not require surgical treatment in their lifetime). The actual probability of DP might be close to the values estimated with Hypothesis C. Of course, this needs be clarified in future studies. These estimations might help physicians and patients in making their decisions on the managements of low-risk PMCs.
The estimated lifetime probability of nodal metastasis fell steadily with each age decade. One might also argue that the appearance of novel nodal metastasis during active surveillance is a failure of this management and that the >10% incidences of nodal metastasis for patients in their 20s and 30s are too high to accept the active surveillance policy. If these patients had been treated at their presentation, the most likely procedure would have been hemithyroidectomy with or without paratracheal dissection. This procedure would not be able to prevent the appearance of nodal metastasis in the lateral neck, and these patients would thus require a second surgery. This was the situation for our patients who underwent immediate surgery. 10 We think that 1 surgery is better than 2 surgeries because the final outcomes seem similarly excellent. 6 It is also well known that the prognosis of clinical or larger PTCs in young patients is very good, although such tumors are often associated with metastatic disease. 11, 12 The surgery used to treat PMCs is relatively easy, but our prior analyses have shown that immediate surgery was associated with significantly higher incidences of unfavorable events (such as vocal cord paralysis and hypoparathyroidism) compared with active surveillance, even though highly experienced endocrine surgeons performed the surgeries. 6, 10 In addition, the medical costs of immediate surgery with 10-year postoperative management were 4.1 times the cost of active surveillance for 10 years. 13 In the present study, we estimated the trends and the lifetime probability of DP, assuming that PMCs progress according to the age decade-specific progression rates over the patient's lifetime. The values of the lifetime probability of DP calculated with the 3 hypotheses described above varied considerably, especially in patients <40 years old. We estimated the lifetime probability of DP during active surveillance using our data of 1,211 patients during up to 23.0 years of active surveillance, but the median surveillance period was only 6.2 years and the numbers of patients in 20s and 30s were <130, which may not be sufficient to draw reliable possibility values. Hypothesis B and Hypothesis C might be valid, but the data that we have are only for the initial 10-year period of active surveillance as a cross-sectional evaluation of our patients and are not the results of following the same patients over many decades. At present, reliable data on the succeeding 10-year periods of active surveillance are not available.
PMCs that may progress after the 10-year time point of active surveillance could be expected to have a very mild progressive nature. Thus, the outcome of a rescue surgery, even if necessary, should be excellent. A further accumulation of data is needed to address the issues accompanying active surveillance versus immediate surgery for PMCs, and to elucidate the natural history of the disease.
We estimated the lifetime probabilities of the progression of PMC during active surveillance based on our actual active surveillance data, using 3 hypotheses. The estimated lifetime probabilities of disease progression vary greatly according to the patients' age at presentation.
Michael Tuttle, MD at Memorial Sloan-Kettering Cancer Center provided critical comments to improve this manuscript. We thank you very much, and excellent presentation. Dr Sareh Parangi (Boston, MA): Dr Miyauchi, I also want to thank you for, A, doing this work, and, B, being kind enough to present it here with us.
I have one question. What about pregnancy? Do you have any data on pregnancy in younger women in that age group? Because that is something I do worry about, and I am not sure how to present that to the patient. Dr Akira Miyauchi: In our institute, there are 2 reports regarding pregnancy. And the first report showed about 40% of the patients had tumor enlargement during pregnancy. But since this is a very important issue, we looked back for all cases. We found that 50 women had 51 pregnancies and delivery events. And the patients who showed an increase in tumor size were only 8%, and none of them showed lymph node appearance.
So, I think pregnancy is a slight risk for disease progression, but it is not necessary to exclude these patients from the active surveillance.
Dr Ashok R. Shaha (New York, NY): Professor Miyauchi, outstanding presentation and great work. I think this is clearly a great service to humanity to monitor thyroid cancer, and I congratulate you and your group for great work.
We have been following your work, and at Sloan-Kettering we have been observing patients for the last ten years, numbering ≈300. And I must say, our data mirror-images your data, exactly the same outcome, the same progression, and the same results.
I would like to change the terminology, active surveillance, to my personal choice, "deferred intervention." What we are trying to do is not really observing the patients but deferring the intervention from today, tomorrow, and trying to see if we can defer the intervention for the rest of their life. And you have shown in your data that in >50% of the patients you can defer surgical intervention.
So, once again, congratulations for a great work. Dr Akira Miyauchi: Thank you very much for your very kind comments.
Dr Christopher R. McHenry (Cleveland, OH): Dr Miyauchi, outstanding work and presentation. Thank you for presenting it here.
I just wanted to know if you could share with us what your surveillance protocol consists of? How do you follow these patients? Dr Akira Miyauchi: The inclusion criteria of the active surveillance is low risk papillary micro cancer. Our definition is very simple: Patients who do not have nodal metastases or distant metastases or patients who show invasion to surrounding tissues, especially for trachea or recurrent laryngeal nerve and patients who do not have aggressive cytology. These are our main definitions. And we also excluded patients that had tumors which were located on the recurrent laryngeal nerve, and the tumor affixing the trachea.
Dr Christopher R. McHenry (Cleveland, OH): So do you follow them?
Dr Akira Miyauchi: We do fine-needle aspiration, and for the first time if the patient chooses observation, we follow the patient with ultrasound 6 months later. Then once a year thereafter. Dr Richard T. Kloos: (Columbus, OH): Congratulations on your beautiful work.
Do you have a hypothesis as to why these patients have different growth rates per decade? Why does a 70-year-old show slower growth than the young person? Is this an intrinsic factor? Dr Akira Miyauchi: Well, this is a really excellent question. You know, another theory reported the very interesting curve. Young patients who had papillary thyroid cancer showed a higher instance of recurrence but a lower incidence of mortality. But elderly patients showed higher incidence of recurrence and higher incidence of mortality. But by some reason I do not know, but by some reason, young, very young patients, middle aged patients, elderly patients have a different biology. That is the only answer for it.
